Patents Examined by Golam M. Shameem
  • Compounds useful as immunomodulators
    Patent number: 11414418
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: August 16, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Juliang Zhu, Paul Michael Scola
  • Aminoalcohol lipidoids and uses thereof
    Patent number: 11414393
    Abstract: Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: August 16, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Kerry Peter Mahon, Kevin Thomas Love, Christopher G. Levins, Kathryn Ann Whitehead, Robert S. Langer, Daniel Griffith Anderson
  • Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2?
    Patent number: 11407712
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: August 9, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Joel Worley Beatty, Samuel Lawrie Drew, Matthew Epplin, Jeremy Thomas Andre Fournier, Balint Gal, Tezcan Guney, Karl T. Haelsig, Clayton Hardman, Steven Donald Jacob, Jenna Leigh Jeffrey, Jaroslaw Kalisiak, Kenneth Victor Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Artur Karenovich Mailyan, Debashis Mandal, Guillaume Mata, Hyunyoung Moon, Jay Patrick Powers, Brandon Reid Rosen, Yongli Su, Anh Thu Tran, Zhang Wang, Xuelei Yan, Kai Yu
  • Heterocyclic compounds as immunomodulators
    Patent number: 11407749
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: August 9, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
  • AXL kinase inhibitors and use of the same
    Patent number: 11400091
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: August 2, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
  • Cancer stem cell inhibitor
    Patent number: 11400076
    Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 2, 2022
    Assignees: KEIO UNIVERSITY, Sun Pharma Japan Limited
    Inventors: Hideyuki Saya, Oltea Sampetrean, Naoyoshi Koike, Nobuo Kubota
  • Proteasome inhibitors
    Patent number: 11396497
    Abstract: The disclosure provides proteasome inhibitors that can be used to halt cell division of rapidly dividing cells by preventing the degradation of cell cycle-regulating proteins, such as cyclins, cyclin-dependent kinase inhibitors, and p53. The proteasome inhibitor compounds can be used to inhibit the proliferation of cancer cells.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: July 26, 2022
    Assignee: NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION
    Inventors: Rodolfo Tello-Aburto, Snezna Rogelj, Liam Hallada, Doleshwar Niroula
  • Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
    Patent number: 11384048
    Abstract: Disclosed in the present invention are an aromatic vinyl or aromatic ethyl derivative, a preparation method therefor, an intermediate, a pharmaceutical composition, and an application. The aromatic vinyl or aromatic ethyl derivative in the present invention is as represented by general formula (I). The aromatic vinyl or aromatic ethyl derivative in the present invention has an obvious inhibitory effect on PD-1/PD-L1, is a very effective small-molecule PD-1/PD-L1 inhibitor, and can effectively alleviate or treat relevant diseases such as cancer.
    Type: Grant
    Filed: December 24, 2018
    Date of Patent: July 12, 2022
    Assignee: GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.
    Inventors: Yuguang Wang, Nong Zhang, Tianzhi Wu, Min He
  • Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
    Patent number: 11370754
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: June 28, 2022
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Michael Van Zandt, Jennifer L. Savoy
  • Systems and methods for production of artificial eumelanin
    Patent number: 11370878
    Abstract: “Black” photoactive materials that comprise synthetic eumelanin polymers are provided, as are methods of making and using the polymers. The synthetic eumelanin polymers are made from the plant oil vanillin, and exhibit defined structural and chemical characteristics (e.g. homogeneity, solubility, etc.) that make them suitable for use in devices that require photoactive materials, such as solar cells.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 28, 2022
    Assignee: The Board of Regents for Oklahoma State University
    Inventor: Toby Larue Nelson
  • Use of a H3R inverse agonist for the treatment of shift work disorder
    Patent number: 11369603
    Abstract: The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: June 28, 2022
    Assignee: NOVARTIS AG
    Inventors: Donald Johns, Klaus Kucher, Judit Sovago
  • Compounds and methods for inhibiting CYP26 enzymes
    Patent number: 11358933
    Abstract: Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: June 14, 2022
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Uttam Saha
  • Method for preparing furfural
    Patent number: 11358943
    Abstract: Provided is a method for preparing furfural. The method comprises: mixing a plant raw material and an acid containing a —SO3H functional group for pre-treating, then mixing same with an organic acid, cooking same, and then subjecting same to solid-liquid separation, so as to obtain a hemicellulose sugar solution; introducing the resulting hemicellulose sugar solution from the upper part of a reaction kettle, and at the same time, introducing an acetic acid steam from the lower part of the reaction kettle, such that the sugar solution and the acetic acid steam come into contact in a counter-current manner and react so as to form a furfural steam; after the reaction is completed, discharging the furfural steam from the upper part of the reaction kettle; and cooling same so as to obtain a solution containing furfural.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 14, 2022
    Assignee: GUANGZHOU YINNOVATOR BIOTECH CO., LTD.
    Inventors: Yunsi Liu, Ruizhe Zhang
  • Opioid receptor modulators and products and methods related thereto
    Patent number: 11352316
    Abstract: Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, B, L, R3, R4, R5, R6, R8, m and n are as defined herein. Such compounds modulate the opioid receptor, particulare the mu-opioid receptor (MOR) and/or the kappa-opioid receptor (KOR), and/or the delta-opioid receptor (DOR). Products containing such compounds, as well as methods for their use and preparation, are also provided.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: June 7, 2022
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Lawrence R McGee, Zhi-Liang Wei, Corinne Sadlowski, Frederick Seidl, Ulhas Bhatt, Xiaodong Wang, Thomas Nguyen, David Sperandio, Pingyu Ding, Alok Nerurkar, Yihong Li, Jason Duquette
  • Benzimidamides compounds comprising an oxaborinin ring
    Patent number: 11352372
    Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: June 7, 2022
    Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: John Liddle, Ann Louise Walker, Gemma Victoria White, Alexis Denis, Nerina Dodic, Marie-Hélène Fouchet, Anne Bouillot
  • Pharmaceutical compounds
    Patent number: 11352342
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X1; X2; R1 and R4 are as defined herein.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Miles Stuart Congreve, Benjamin Gerald Tehan, Barry John Teobald
  • Method for producing carbamate and method for producing isocyanate
    Patent number: 11352319
    Abstract: The present invention provides a method for producing a carbamate that includes a step (1) and a step (2) described below: (1) a step of producing a compound (A) having a urea linkage, using an organic primary amine having at least one primary amino group per molecule and at least one compound selected from among carbon dioxide and carbonic acid derivatives, at a temperature lower than the thermal dissociation temperature of the urea linkage; and (2) a step of reacting the compound (A) with a carbonate ester to produce a carbamate.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: June 7, 2022
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventors: Nobuhisa Miyake, Koichi Nakaoka, Yusuke Sakurai, Midori Nagamoto, Kazuhiro Takagaki, Masaaki Shinohata
  • TGR5 modulators and methods of use thereof
    Patent number: 11345721
    Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: May 31, 2022
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
  • A2-73 as a therapeutic for insomnia, anxiety, and agitation
    Patent number: 11337953
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: May 24, 2022
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • hTRPV1 chemical agents
    Patent number: 11339122
    Abstract: Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such compounds.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: May 24, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Xiang-Qun Xie, Zhiwei Feng